Get the Stockscreener App
1.20
4.34%
-0.06
Fate Therapeutics Inc stock is traded at $1.20, with a volume of 1.16M.
It is down -4.34% in the last 24 hours and down -0.39% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.26
Open:
$1.24
24h Volume:
1.16M
Relative Volume:
0.56
Market Cap:
$138.97M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.7273
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-19.11%
1M Performance:
-0.39%
6M Performance:
-7.99%
1Y Performance:
-56.33%
1-Day Range:
$1.20
$1.3082
1-Week Range:
$1.20
$1.505
52-Week Range:
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.205 | 145.32M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.49 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.97 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.79 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.66 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - sharewise.com
How Fate Therapeutics Inc. stock benefits from global expansion2025 Technical Overview & Fast Momentum Entry Tips - newser.com
How to use a screener to detect Fate Therapeutics Inc. breakoutsJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Will Fate Therapeutics Inc. see short term momentumJuly 2025 Sector Moves & Verified Short-Term Plans - newser.com
What Fibonacci levels say about Fate Therapeutics Inc. reboundWeekly Trade Report & Capital Efficient Trading Techniques - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturnsVolume Spike & Technical Confirmation Trade Alerts - newser.com
Can trapped investors hope for a rebound in Fate Therapeutics Inc.Weekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Why Fate Therapeutics Inc. stock remains a top recommendation2025 Retail Activity & Real-Time Volume Triggers - newser.com
Developing predictive dashboards with Fate Therapeutics Inc. dataWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Why Fate Therapeutics Inc. stock is a value investor pick2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Q3 Earnings Estimate for FATE Issued By HC Wainwright - MarketBeat
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Multi factor analysis applied to Fate Therapeutics Inc.Earnings Growth Summary & Entry Point Strategy Guides - newser.com
Automated trading signals detected on Fate Therapeutics Inc.2025 Analyst Calls & AI Driven Stock Reports - newser.com
Will Fate Therapeutics Inc. stock recover faster than marketAnalyst Upgrade & Smart Investment Allocation Insights - newser.com
Is Fate Therapeutics Inc. stock undervalued vs historical averagesSell Signal & Free Safe Entry Trade Signal Reports - newser.com
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Fate Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
HC Wainwright & Co. Upgrades Fate Therapeutics (FATE) - Nasdaq
HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target - MarketScreener
Q3 Earnings Forecast for Fate Therapeutics Issued By Wedbush - MarketBeat
What drives Fate Therapeutics Inc stock priceVolume Weighted Average Price & Low Cost Trading Plans - earlytimes.in
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):